Updated: In light of the unprecedented COVID-19 situation, we have extended the pre-proposal deadline for current funding opportunities to May 14, 2020. For additional information, review our FAQs on COVID-19 and research support.
The Michael J. Fox Foundation (MJFF) is now accepting pre-proposals for fall 2020 funding. The four open funding programs, listed below, span our strategy to define, measure and treat Parkinson’s. These programs are open to researchers in non- and for-profit organizations both within and outside the United States.
- Investigating Environmental Factors that Increase the Risk for Parkinson’s Disease: Funds use of existing datasets to identify and/or quantify environmental exposures that influence Parkinson’s risk or progression.
- Target Advancement Program: Funds research to validate targets and define pathways implicated in Parkinson’s pathological processes and/or symptomology.
- Parkinson’s Pathway Biomarkers: Funds research aimed at (1) developing sensitive readouts for pathway activation/dysfunction and (2) improving technologies for analyzing the target/pathway of interest.
- Therapeutic Pipeline Program: Funds novel or repositioned, pre-clinical and clinical therapeutic intervention development for Parkinson’s. Specific interest in (1) developing therapeutics for non-motor symptoms and (2) early drug discovery for novel targets with few or no candidates in development.
To learn more about MJFF’s funding strategy, these four open RFAs, and the application and review processes, attend our webinar at noon ET on March 27, 2020. You can also visit the Funding Opportunities page to learn more.
The Target Advancement and Therapeutic Pipeline programs are Edmond J. Safra Core Programs for PD Research.